Pay in 4 interest-free payments of $5.01 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
A Personalized Approach recognizes that each body responds differently to treatment
GLP-1 Consumer and Employer Surveys Provide Key Insights into Market Growth Meaningful uptake of weight loss drugs in the primary care setting will be critical to achieve peak potential
Semaglutide is the top driver for prescription demand both in hospitals and retail pharmacies
Novo Nordisk reined in its growth forecasts for the year in its second-quarter financial results update, blaming "persistent use of compounded GLP-1s, slower-than-expected market expansion, and competition." Compounding of semaglutide should have come to a halt in the US since the drug was removed from the FDA list of medicines in short supply, but various companies continue to provide compounded GLP-1s under a loophole that allows the sale of 'personalised' formulations
